Edition:
United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

9.49USD
5:54pm BST
Change (% chg)

$-0.50 (-5.01%)
Prev Close
$9.99
Open
$9.95
Day's High
$10.02
Day's Low
$9.36
Volume
85,811
Avg. Vol
172,530
52-wk High
$27.23
52-wk Low
$9.36

Robbins, Leslie 

Ms. Leslie Robbins, J.D. is Senior Vice President - Intellectual Property of the company. Ms. Robbins has over 25 years of legal and intellectual property strategic experience within the biotechnology and pharmaceutical industries. Ms. Robbins joins CytomX from Coherus BioSciences where she held the role of vice president, intellectual property and was responsible for, among other things, the execution of legal strategies in support of the biosimilar platform. Prior to this, she held senior intellectual property counsel roles at Onyx Pharmaceuticals (acquired by Amgen) where she provided strategy and advice on intellectual property related matters related to KYPROLIS® and Elan Pharmaceuticals where she oversaw all intellectual property matters related to TYSABRI®, the company's humanized antibody product. Ms. Robbins began her career at Chiron Corporation and later joined the law firm of Burns, Doane, Swecker & Mathis where she prepared and prosecuted U.S. and foreign patent applications in the biotechnology and pharmaceutical fields. Ms. Robbins received her B.A. degree in microbiology and immunology from the University of California, Berkeley and her J.D. from the Illinois Institute of Technology's Chicago-Kent College of Law.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

3,213,340

Debanjan Ray

1,563,120

Nick Galli

--

Leslie Robbins

--

W. Michael Kavanaugh

1,382,260

Rachel Humphrey

1,539,700
As Of  31 Dec 2017